|
|
 |
|
Viewing report
|
|
|
|
U.S. Drug Delivery Systems Market: Emerging Technologies, Strategic Alliances, Patent Disputes, Market Size and Forecasts and R&D Activities
Fuji-Keizai USA, Inc, Jan 2003, Pages: 145
This report is about drug delivery systems, what they do for pharmaceutical products, why they are needed, and the extent of this important technology market.
Most people think of drug delivery systems as the added ingredients that go into oral pills that people take for all-day headache pain relief, a patch that helps people stop smoking or an inhaler to help a child with asthma breathe easier. It is this and more. It is an interesting, prospering US industry that is transforming ordinary drugs into drugs optimized for their targeted applications.
Drug delivery is an enabling technology that is helping to expand other pharmaceutical industry sectors such as generic drugs and specialty pharmaceuticals. The technology is being used by some pharmaceutical firms to differentiate their products so that new opportunities can be created. Other companies are adding special drug delivery features to products to extend the marketing life of product lines. The industry definition has expanded to include new, targeted therapies as well as new drug containing implants that were invented by emerging companies. Monoclonal antibodies, gene delivery, Mems implants and drug-coated stents are examples of emerging drug delivery innovations.
This study has found that the market size for drug delivery systems in 2002 is about $47 billion and is projected to grow to about $67 billion in 2006 with a Cagr of nearly 8%. While the pharmaceutical industry generated about $250 billion in 2001, it faces numerous issues that could be helped with advanced or emerging drug delivery systems. Many of their highly profitable blockbuster drugs will reach patent expiry by 2004-2006 and lose about $37 billion in market value to generic competition. Growing through mergers has not helped much. Optimizing products through drug delivery might be a better strategy.
The report discusses these important issues with interesting and useful findings. This study uses more than 30 figures and tables to illustrate the findings.
Detailed information about the activities of companies important to the expanding drug delivery market are profiled.
Available in English or Japanese.
|
|
|
|
